<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04706039</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_1148</org_study_id>
    <nct_id>NCT04706039</nct_id>
  </id_info>
  <brief_title>Rapid Diagnosis of COVID-19 by Chemical Analysis of Exhaled Air</brief_title>
  <acronym>COVIDAIR</acronym>
  <official_title>Rapid Diagnosis of COVID-19 by Chemical Analysis of Exhaled Air</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the start of 2020, the new SARS-CoV-2 coronavirus is causing a real global health&#xD;
      crisis.&#xD;
&#xD;
      In France, nasopharyngeal swabs are used to obtain the sample needed for respiratory&#xD;
      infection screening. There are three major difficulties with this type of sampling:&#xD;
&#xD;
      I) It is really unpleasant for the patient because the device has to be pushed into the&#xD;
      nostril to reach the nasopharynx. It causes some patients to bleed or even feel&#xD;
      uncomfortable.&#xD;
&#xD;
      II) It is not easily accepted by children. III) It is dependent on the availability of swabs.&#xD;
      Faced with these difficulties linked to the initial sampling, new methods are being studied&#xD;
      to enable a rapid and non-invasive diagnosis of COVID-19 based on the instantaneous&#xD;
      identification of metabolites or volatile organic compounds (VOCs).&#xD;
&#xD;
      Due to their sensitivity and the wealth of information that can be provided, the most&#xD;
      promising techniques are based on mass spectrometry coupled with a soft ionisation system.&#xD;
      For example, on-line exhaled air analysis is capable of detecting a very large number of&#xD;
      VOCs. Various tests on metabolites in the exhaled air have already been carried out without&#xD;
      being totally conclusive because the existing instruments suffer from various limitations:&#xD;
&#xD;
      I) poor repeatability/accuracy in the chemical characterisation of exhaled air ; II) too high&#xD;
      specificity (detection of only part of the emitted compounds); III) too limited sensitivity;&#xD;
      IV) and poor adaptation to be deployed in a clinic.&#xD;
&#xD;
      In order to overcome these various limitations, we propose the use of a new generation of&#xD;
      mass spectrometer: Vocus PTR-TOF. The Vocus PTR-TOF is a Proton Transfer Mass Spectrometer&#xD;
      (PTR-MS) developed for the detection, in real time, of trace VOCs in industrial environments,&#xD;
      laboratories or directly in the environment. This new generation of instrument offers the&#xD;
      following advantages:&#xD;
&#xD;
      I) unequalled sensitivity :&#xD;
&#xD;
      II) a robust ionisation system not affected by environmental conditions (relative&#xD;
      humidity...) ; III) a high mass resolution allowing precise identification of compounds ; IV)&#xD;
      a compact and durable architecture allowing deployment in a constrained environment such as&#xD;
      hospital, airport… The sensitivity and speed of measurement allow the expiration process to&#xD;
      be monitored in real time, bringing an additional dimension to the measurement and the&#xD;
      chances of success.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of the COVID-19 diagnostic using the Vocus PTR-TOF process.</measure>
    <time_frame>At the inclusion visit</time_frame>
    <description>Study of the sensitivity of the exhaled air test in comparison to the reference diagnostic RT-PCR on nasopharyngeal swab. We will use the results of the RT-PCR as reference to compare the results of the Vocus PTR-TOF process.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Outpatients without hospitalisation criteria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symptomatic and asymptomatic outpatient without hospitalisation criteria presenting in a COVID-19 screening centre of the Hospices Civils de Lyon</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Performance evaluation (sensitivity and specificity) for COVID-19 diagnosis of the Vocus PTR-TOF process</intervention_name>
    <description>Each patient will be sampled to do a systematic respiratory virus infection screening (SARS-CoV-2 and Flu and RSV). Then each patient will be tested using the Vocus PTR-TOF process.&#xD;
A self-answering questionnaire will be used to collect symptomatology information and date of onset of symptoms.</description>
    <arm_group_label>Outpatients without hospitalisation criteria</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic and asymptomatic outpatient without hospitalisation criteria&#xD;
&#xD;
          -  No medical contraindications to nasopharyngeal swabbing (deviation of the nasal&#xD;
             septum, epistaxis, anticoagulant treatment).&#xD;
&#xD;
          -  Patient able to blow into the test device&#xD;
&#xD;
          -  Patients or parents with parental authority who have been informed of the study and&#xD;
             have not objected to participating in it&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major subject under guardianship or curatorship or unable to consent to study.&#xD;
&#xD;
          -  Subject under safeguard of justice&#xD;
&#xD;
          -  Minor patient (age &lt; 6 years).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexandre GAYMARD, MD</last_name>
    <phone>04.72.07.10.53</phone>
    <email>alexandre.gaymard@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian GEORGE, MD</last_name>
    <phone>04.72.44.81.90</phone>
    <email>Christian.George@ircelyon.univ-lyon1.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de prélèvement COVID-19 HCL et Métropole de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre GAYMARD, MD</last_name>
      <phone>04.72.07.10.53</phone>
      <email>alexandre.gaymard@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid19 diagnostic</keyword>
  <keyword>Proton Transfer Mass Spectrometer</keyword>
  <keyword>exhaled air</keyword>
  <keyword>rapid and non-invasive diagnosis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

